Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

C4 THERAPEUTICS, INC.

(CCCC)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/21/2022 01/24/2022 01/25/2022 01/26/2022 01/27/2022 Date
23.4(c) 23.99(c) 23.19(c) 22.08(c) 20.53 Last
545 507 735 597 446 654 292 817 382 625 Volume
-4.26% +2.52% -3.33% -4.79% -7.02% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 33,0 M - -
Net income 2021 -96,9 M - -
Net cash position 2021 378 M - -
P/E ratio 2021 -10,5x
Yield 2021 -
Sales 2022 30,6 M - -
Net income 2022 -125 M - -
Net cash position 2022 286 M - -
P/E ratio 2022 -9,15x
Yield 2022 -
Capitalization 1 074 M 1 074 M -
EV / Sales 2021 21,1x
EV / Sales 2022 25,7x
Nbr of Employees 99
Free-Float -
More Financials
Company
C4 Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on harnessing the bodyÔÇÖs natural regulation of protein levels to develop therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. The Company provides technology platform, Target ORiented ProtEin Degrader Optimizer (TORPEDO), to synthesize a new... 
More about the company
Ratings of C4 Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about C4 THERAPEUTICS, INC.
01/21C4 THERAPEUTICS : Financial Statements - Form 8-K/A
PU
01/21C4 THERAPEUTICS, INC. Financial Statements and Exhibits (form 8-K/A)
AQ
01/10C4 Therapeutics Says Liquidity Position Sufficient Through 2024; Shares Climb
MT
01/10C4 THERAPEUTICS : Announces 2022 Key Milestones to Advance Targeted Protein Degradation Po..
PU
01/10C4 THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Discl..
AQ
01/10C4 THERAPEUTICS : Corporate Presentation – January 2022
PU
01/10C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation P..
GL
01/10C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation P..
CI
01/03C4 Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
GL
2021C4 THERAPEUTICS : CFT7455 ASH Trial-in-Progress Poster Presentation
PU
2021C4 THERAPEUTICS, INC.(NASDAQGS : CCCC) added to NASDAQ Biotechnology Index
CI
2021C4 Therapeutics to Join NASDAQ Biotechnology Index
MT
2021C4 Therapeutics Added to NASDAQ Biotechnology Index
GL
2021C4 THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Creation of a Direct F..
AQ
2021BofA Securities Starts C4 Therapeutics at Buy With $54 Price Target
MT
More news
News in other languages on C4 THERAPEUTICS, INC.
01/10C4 Therapeutics déclare que sa position de liquidité est suffisante jusqu'en 2024 ; les..
01/10C4 Therapeutics annonce 2022 étapes clés pour faire progresser le portefeuille de dégra..
2021C4 Therapeutics rejoint l'indice biotechnologique du NASDAQ
2021C4 Therapeutics réduit sa perte au deuxième trimestre et augmente son chiffre d'affaire..
2021C4 Therapeutics propose un placement d'actions ordinaires à 37 $ par action.
More news
Analyst Recommendations on C4 THERAPEUTICS, INC.
More recommendations
Chart C4 THERAPEUTICS, INC.
Duration : Period :
C4 Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends C4 THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 22,08 $
Average target price 60,67 $
Spread / Average Target 175%
EPS Revisions
Managers and Directors
Andrew J. Hirsch President, Chief Executive Officer & Director
Lauren White Treasurer, Chief Financial & Accounting Officer
Marc A. Cohen Executive Chairman
Adam S. Crystal Chief Medical Officer
Stewart Fisher Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
C4 THERAPEUTICS, INC.-31.43%1 074
MODERNA, INC.-38.99%62 828
LONZA GROUP AG-20.54%48 784
IQVIA HOLDINGS INC.-17.54%44 443
SEAGEN INC.-20.08%22 592
ICON PUBLIC LIMITED COMPANY-18.28%20 601